VanEck Pharmaceutical ETF (PPH) is a publicly traded the market company. As of May 21, 2026, PPH trades at $102.63 with a market cap of $0 and a P/E ratio of 0.00. PPH moved +0.16% today. Year to date, PPH is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $0.00 to $0.00. Rallies surfaces PPH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Merck Secures AI Deal with Mayo Clinic to Accelerate IBD and MS Therapies: Merck has entered a first-of-its-kind strategic collaboration with the world’s top-ranked Mayo Clinic to utilize its extensive multimodal clinical and laboratory data for AI-driven drug discovery. The partnership will initially target inflammatory bowel disease, atopic dermatitis and multiple sclerosis to accelerate tailored therapy development.
| Metric | Value |
|---|---|
| Price | $102.63 |
| Market Cap | $0 |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $0.00 |
| 52-Week Low | $0.00 |
| Volume | 125.21K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
PPH analyst coverage data. Average price target: $0.00.